Auhtors: Li X, Liu R, Su X, Pan Y, Han X, Shao C, Shi Y
PMID: 31805946 PMCID: PMC6894344 DOI: 10.1186/s12943-019-1102-3
Abstract
Cancer immunotherapies that engage immune cells to fight against tumors are proving to be powerful weapons in combating cancer and are becoming increasingly utilized in the clinics. However, for the majority of patients with solid tumors, little or no progress has been seen, presumably due to lack of adequate approaches that can reprogram the local immunosuppressive tumor milieu and thus reinvigorate antitumor immunity. Tumor-associated macrophages (TAMs), which abundantly infiltrate most solid tumors, could contribute to tumor progression by stimulating proliferation, angiogenesis, metastasis, and by providing a barrier against antitumor immunity. Initial TAMs-targeting strategies have shown efficacy across therapeutic modalities and tumor types in both preclinical and clinical studies. TAMs-targeted therapeutic approaches can be roughly divided into those that deplete TAMs and those that modulate TAMs activities. We here reviewed the mechanisms by which macrophages become immunosuppressive and compromise antitumor immunity. TAMs-focused therapeutic strategies are also summarized.
Keywords: Combination therapy; Immune checkpoint blockade; Immunotherapy; Tumor immunology; Tumor-associated macrophage.
Source: https://pubmed.ncbi.nlm.nih.gov/31805946/
Archive: https://archive.is/ZsX40
